Erika Hamilton, Chair, Executive Committee, Breast and Breast Program Lead at Sarah Cannon Research Institute, shared a post on X:
“ASCENT04 now out in NEJM. 7.8 to 11.2 months PFS with saci/pembro over chemo pembro in 1st line PDL1+ TNBC.”
Title: Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
Authors: Sara M Tolaney, Evandro de Azambuja, Kevin Kalinsky, Sherene Loi, Sung Bae Kim, Clinton Yam, Bernardo Rapoport, Seock Ah Im, Barbara Pistilli, Wassim Mchayleh, David W Cescon, Junichiro Watanabe, Manuel Alejandro Lara Banuelas, Ruffo Freitas Junior, Javier Salvador Bofill, Maryam Afshari, Dianna Gary, Lu Wang, Catherine Lai, Peter Schmid
